Data processing: structural design – modeling – simulation – and em – Simulating nonelectrical device or system – Biological or biochemical
Reexamination Certificate
2002-07-31
2008-08-26
Borin, Michael (Department: 1631)
Data processing: structural design, modeling, simulation, and em
Simulating nonelectrical device or system
Biological or biochemical
C702S019000, C703S002000
Reexamination Certificate
active
07418374
ABSTRACT:
A computer-implemented method for determining an optimal treatment protocol for a disease related to angiogenesis, comprising creating an angiogenesis model including pro-angiogenic and anti-angiogenic factors. Effective vessel density (EVD) is incorporated as a factor regulating switching on and switching off of at least one component in the angiogenesis model. Effects of vasculature maturation and mature vessel destabilization are incorporated. Pro-angiogenic and anti-angiogenic factors, which can influence changes in state of a tissue, are selected. Effects of drugs in the pro-angiogenic and anti-angiogenic factors are incorporated. A plurality of treatment protocols in a protocol space is generated. A best treatment protocol based on a pre-determined criteria is selected.
REFERENCES:
Guidi et al. Database CaPlus, DN:136:318985. Journal of Clinical Oncology (2002), 20(3), 732-742.
Hahnfeldt P. et al. (1999) Tumor development under angiogenic signaling: a dynamic theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res. 59:4770-4775.
Anderson AR and Chaplain MA (1998) Continuous and discrete mathematical models of tumor-induced angiogenesis. Bull Math Biol. 604(5):857-99.
Tong S and Yuan F (2001) Numelical simulations of angiogenesis in the cornea. Microvasc Res; 6141): 14-27.
Augustin et al. American Journal of Pathology, 147 (2), 339-351, 1995.
Anderson et al Bulletin of Mathematical Biology, 60, 857-900, 1998.
Lissbrant et al . Prostate, 33:38-45, 1997.
Folkman, J., Angiogenesis in cancer, vascular, rheumatoid and other disease, Nat Med., 1995, pp. 27-31, vol. 1(1).
Carmeliet, P. et al, Angiogenesis in cancer and other diseases, Nature, 2000, pp. 249-257, vol. 407.
Yancopoulos, G.D. et al, Vascular-specific growth factors and blood vessel formation, Nature, 2000, pp. 242-248, vol. 407.
Kerbel, R.S., Tumor angiogenesis: past, present and the near future, Carcinogenesis, 2000, pp. 505-515, vol. 21(3).
Danielsen, T et al, The constitutive level of vascular endothelial growth factor (VEGF) is more important than hypoxia-induced VEGF up-regulation in the angiogenesis of human melanoma xenografts, Br. J. Can., 2000, pp. 1528-1534, vol. 82(9).
Dor, Y. et al, Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis, AJP-Cell Physiology, 2001, pp. C1367-C1374, vol. 280(6).
Ikeda, E et al, Hypoxia-induced Transcriptional Activation and Increased mRNA Stability of Vascular Endothelial Growth Factor in C6 Glioma Cells, J. Biol. Chem., 1995, pp. 19761-19766, vol. 270(34).
Ferrara, N. et al, Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells, BBRC, 1989. PP. 851-858, vol. 161(2).
Ferrara, N. et al, Molecular and biological properties of the vascular endothelial growth factor family of proteins, Endocr Rev, 1992, pp. 18-32, vol. 13(1).
Breier, G. et al, Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation, Development, 1992, pp. 521-532, vol. 114.
Keyt, B. et al. Identification of VEGF determinants for binding KDR and Flt-1 receptors. J Biol. Chem., 1996, pp. 5638-5646, vol. 271(10).
Ferrara, N. et al, Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene, Nature, 1996, pp. 439-442, vol. 380.
Carmeliet, P. et al, Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele, Nature, 1996, pp. 435-439, vol. 380.
Barleon, B. et al, Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1, Blood, 1996, pp. 3336-3343, vol. 87(8).
Neufeld, G. et al, Vascular endothelial growth factor (VEGF) and its receptors, FASEB. 1999, pp. 9-22, vol. 13.
Kim, K.J. et al, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo, Nature, 1993, pp. 841-844, vol. 362.
Potgens, A. et al, Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice, Am. Jour. Pathol., 1995, pp. 197-209, vol. 146(1).
Claffrey, K.P. et al, Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis, Cancer Res., 1996, pp. 172-181, vol. 56(1).
Shweiki, D. et al, Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis, Nature, 1992, pp. 843-845, vol. 359.
Dvorak, H.F. et al, Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis, Am J Pathol, 1995, pp. 1029-1039, vol. 146(5).
Benjamin, L.E. et al, Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawl, PNAS. 1997. pp. 8761-8766, vol. 94.
Jain R.K. et al, Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor, PNAS, 1998, pp. 10820-10825, vol. 95(18).
Holash, S.J. et al, New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF, Oncogene, 1999, pp. 5356-5362, vol. 18.
Gilead, A. et al, Dynamic remodeling of the vascular bed precedes tumor growth: MLS ovarian carcinoma spheroids implanted in nude mice, Neoplasia, 1999, pp. 226-230, vol. 1(3).
Benjamin, L.E. et al, Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal, J Clin Invest., 1999, pp. 159-165, vol. 103(2).
Benjamin, L.E. et al, A plasticity window for blood vessel remodeling is defined by pencyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF, Development, 1998, pp. 1591-1598, vol. 125(9).
Grosskreutz, C.L. et al, Vascular Endothelial Growth Factor-Induced Migration of Vascular Smooth Muscle Cells in Vitro, Microvascular Research, 1999, pp. 128-136. vol. 58.
Lindahl, P. et al, Pericyte Loss and Microaneurysm Formation in PDGF-B-Deficient Mice, Science, 1997, pp. 242-245, vol. 277.
Hellstrom, M. et al, Role PDGF-B and PDGFR-b in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse Development, 1999, pp. 3047-3055, vol. 126.
Davis, S. et al, Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning, Cell, 1996, pp. 1161-1169, vol. 87.
Suri, C. et al, Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis, Cell, 1996. pp. 1171-1180. vol. 87.
Maisonpierre, P.C. et al, Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis, Science, 1997, pp. 55-60. vol. 277.
Folkman, J. et al, Blood Vessel Formation: What Is Its Molecular Basis?. Cell, 1996, pp. 1153-1155. vol. 87.
Eggert, A. et al, High-Level Expression of Angiogenic Factors Is Associated with Advanced Tumor Stage in Human Neuroblastomas. Clin. Can. Res., 2000, pp. 1900-1908. vol. 6.
Loughna, S. et al, Angiopoietin and Tie signaling pathways in vascular development, Matrix Biol., 2001, pp. 319-325, vol. 20.
Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 1971, pp. 1182-1186, vol. 285(21).
O'Reilly, M.S. et al, Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metaslases by a Lewis lung carcinoma, Cell, 1994, pp. 315-328, vol. 79.
O'Reilly, M.S. et al, Endostatin: an endogenous inhibitor of angiogenesis and tumor growth, Cell, 1997, pp. 277-285, vol. 88.
Anderson, A.R. et al, Continuous and discrete mathematical models of tumor-induced angiogenesis, Bull Math Biol., 1998, pp. 857-899. vol. 60(5).
Hahnfeldt, P. et al, Tumor development under angiogenic signaling: a dynamic theory of tumor growth, treatment response, and postvascular dormancy, Cancer Res., 1999, pp. 4770-4775, vol. 59.
Rolland, Y. et al, Modeling of the parenchymous vascularization an
Agur Zvia
Arakelyan Levon
Vainstein Vladimir
Borin Michael
OPTIMATA
Sughrue & Mion, PLLC
LandOfFree
Treatment protocol generation for diseases related to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment protocol generation for diseases related to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment protocol generation for diseases related to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4013994